DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Sutab (copackaged) is a drug marketed by Braintree Labs and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in SUTAB (COPACKAGED) is magnesium sulfate; potassium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the magnesium sulfate; potassium chloride; sodium sulfate profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 10, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SUTAB (COPACKAGED)
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SUTAB (COPACKAGED)
ATC Classes for SUTAB (COPACKAGED)
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Braintree Labs||SUTAB (COPACKAGED)||magnesium sulfate; potassium chloride; sodium sulfate||TABLET;ORAL||213135-001||Nov 10, 2020||RX||Yes||Yes||Get Started Free||Get Started Free||Y||Get Started Free|
|Braintree Labs||SUTAB (COPACKAGED)||magnesium sulfate; potassium chloride; sodium sulfate||TABLET;ORAL||213135-001||Nov 10, 2020||RX||Yes||Yes||Get Started Free||Get Started Free||Get Started Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|